View profile

FarmaKology Newsletter - Issue #48

Would you like to submit an article, some interesting news, or get your startup featured? Send whatev


June 10 · Issue #48 · View online
FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to, and happy to have you featured on our newsletter (+5555 Subscribers ) !

Today's Startup
 BioXcel Therapeutics
BioXcel Therapeutics
BioXcel Therapeutics
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company’s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
Singapore is starting its first human trial for a drug to treat Covid-19. A total of 23 healthy volunteers here have been selected to join a clinical safety trial for an antibody drug that is could potentially be a viable treatment for Covid-19 patients. The Phase 1 clinical safety trial will start next week and last some six weeks. The Health Sciences Authority granted approval for the trial on June 8. The biotech company, Tychan, is behind the treatment. This is the first time an in-human trial for a Covid-19 treatment medicine has been approved in Singapore.  Tychan said in a statement on June 10 that it produced this antibody on Feb. 25.
Two UK drugs companies will be the first to partner with the Universities of Birmingham and Oxford as part of a major new UK drugs trial to test potential therapeutics to treat patients hospitalised with COVID-19. In what could be a significant development in the fight against the virus the CATALYST trial, which is a collaboration with University Hospitals Birmingham NHS Foundation Trust (UHB), will test a series of new drugs, including those already in use for patients with cancer and inflammatory diseases such as rheumatoid arthritis.
The Central Drugs Standard Control Organization (CDSCO) has reportedly given approval for a potential chemical entity developed by CSIR’s Indian Institute of Integrative Medicine (IIIM) in Jammu. This potent anti-cancer drug is anticipated to be effective for the treatment of pancreatic cancer after it successfully completes preclinical development and Investigational New Drug submission. This significant milestone has been achieved by a team of scientists including Sonali Bharate, Sandip Bharate, Shashi Bhushan, Dilip Mondhe, and Sumit Gandhi, complemented Dr. Shekhar Mande, the DG at CSIR.
 Illumina, Inc. is paving the way for large-scale, next-generation sequencing-based COVID-19 testing. Today, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization for the Illumina COVIDSeq™ Test, a high-throughput, sequencing-based, in vitro diagnostic (IVD) workflow enabling the detection of SARS-CoV-2. The end-to-end workflow extends the options available for labs to scale diagnostic testing.
Research & Study
Podcast: Retracted hydroxychloroquine-COVID studies spark backlash; Cancer drugs for obesity? 'Unbiased' Guardian takes animal rights money | Genetic Literacy Project
Job Opportunities
Upcoming Webinar
Supporting service operations amid the COVID 19 outbreak
Did you enjoy this issue?
If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue